The Prevalence of Metabolic Syndrome in Patients Treated with Atypical Antipsychotics in an Outpatient Health Clinic

Persistent Link:
http://hdl.handle.net/10150/614182
Title:
The Prevalence of Metabolic Syndrome in Patients Treated with Atypical Antipsychotics in an Outpatient Health Clinic
Author:
Deeren, Thomas; Kent, Tanya; Sanzenbacher, Robert; Goldstone, Lisa; Kennedy, Amy
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2014
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Specific Aims: To determine the prevalence of metabolic syndrome (MetS) in patients treated in an outpatient clinic that were taking atypical antipsychotics. Methods: This retrospective chart review included 822 adults diagnosed with various personality/mood disorders. Age, gender, ethnicity, blood pressure, height, weight, lipid panels, fasting blood glucose, and second-generation antipsychotic (SGA) used and treatment length were obtained. Patients were separated into two groups: those who were not taking an SGA in/for the past three months (group 1), and those taking at least one SGA for a minimum of three months (group 2). MetS was determined using NCEP ATP III guidelines. The primary outcome measured was the difference in the prevalence of MetS between each group. Main Results: At baseline, 753 patients were in group 1 and 69 patients were in group 2, there was a higher percentage of females in group 1 (p<0.0001), and a higher percentage of males in group 2 (p<0.0001). No difference was seen with age, and weight, (p=0.294, p=0.625, respectively). There were more patients reported as Caucasian in group 2 (p=0.0001) and more reported as Caucasian/Hispanic in group 1 (p=0.0001). The rate of MetS between group 1 (54.45%) and group 2 (59.42%) was not statistically different (p = 0.427). Conclusion: No statistical difference was found in the rate of MetS between the two groups. Removing confounding drugs known to cause weight gain did not change these results.
Description:
Class of 2014 Abstract
Keywords:
metabolic syndrome (MetS); Atypical Antipsychotics; Outpatient; Prevalence
Advisor:
Goldstone, Lisa; Kennedy, Amy

Full metadata record

DC FieldValue Language
dc.contributor.advisorGoldstone, Lisaen
dc.contributor.advisorKennedy, Amyen
dc.contributor.authorDeeren, Thomasen
dc.contributor.authorKent, Tanyaen
dc.contributor.authorSanzenbacher, Roberten
dc.contributor.authorGoldstone, Lisaen
dc.contributor.authorKennedy, Amyen
dc.date.accessioned2016-06-22T19:31:19Z-
dc.date.available2016-06-22T19:31:19Z-
dc.date.issued2014-
dc.identifier.urihttp://hdl.handle.net/10150/614182-
dc.descriptionClass of 2014 Abstracten
dc.description.abstractSpecific Aims: To determine the prevalence of metabolic syndrome (MetS) in patients treated in an outpatient clinic that were taking atypical antipsychotics. Methods: This retrospective chart review included 822 adults diagnosed with various personality/mood disorders. Age, gender, ethnicity, blood pressure, height, weight, lipid panels, fasting blood glucose, and second-generation antipsychotic (SGA) used and treatment length were obtained. Patients were separated into two groups: those who were not taking an SGA in/for the past three months (group 1), and those taking at least one SGA for a minimum of three months (group 2). MetS was determined using NCEP ATP III guidelines. The primary outcome measured was the difference in the prevalence of MetS between each group. Main Results: At baseline, 753 patients were in group 1 and 69 patients were in group 2, there was a higher percentage of females in group 1 (p<0.0001), and a higher percentage of males in group 2 (p<0.0001). No difference was seen with age, and weight, (p=0.294, p=0.625, respectively). There were more patients reported as Caucasian in group 2 (p=0.0001) and more reported as Caucasian/Hispanic in group 1 (p=0.0001). The rate of MetS between group 1 (54.45%) and group 2 (59.42%) was not statistically different (p = 0.427). Conclusion: No statistical difference was found in the rate of MetS between the two groups. Removing confounding drugs known to cause weight gain did not change these results.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectmetabolic syndrome (MetS)en
dc.subjectAtypical Antipsychoticsen
dc.subjectOutpatienten
dc.subjectPrevalenceen
dc.titleThe Prevalence of Metabolic Syndrome in Patients Treated with Atypical Antipsychotics in an Outpatient Health Clinicen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.